Page last updated: 2024-12-07

cytidylyl-3',5'-adenosine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Cytidylyl-3',5'-adenosine (CpA) is a dinucleotide composed of cytidine and adenosine linked by a 3',5'-phosphodiester bond. It is a common component of RNA and is involved in various cellular processes, including protein synthesis, RNA splicing, and signal transduction. CpA has been shown to have both stimulatory and inhibitory effects on cell growth, depending on the context. For example, CpA has been shown to inhibit the growth of certain cancer cells. It has also been shown to stimulate the immune system. CpA is studied for its potential therapeutic applications, including cancer treatment and immune modulation. It is synthesized through enzymatic reactions involving RNA polymerase or DNA polymerase, depending on the specific context. The synthesis and breakdown of CpA are tightly regulated within cells, and dysregulation can lead to various diseases.'

cytidylyl adenosine: CPA removed as SY because it is also used as an abbreviation for N6-cyclopentyladenosine, CYCLOPHOSPHAMIDE, and cyclopiazonic acid [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID91519
MeSH IDM0062039

Synonyms (16)

Synonym
cpa (van)
cytidine, adenylyl-(5'-3')-
cytidylyl adenosine
einecs 219-187-7
cytidylyl(3'.5')adenosine
nsc 91552
adenylyl-(3'-->5')-cytidine
[(2r,3s,4r,5r)-5-(4-amino-2-oxopyrimidin-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r,3s,4r,5r)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methyl hydrogen phosphate
adenosine, cytidylyl-(3'-5')-
cytidilyl-3',5'-adenosine
cytidylyl-(3'-5')-adenosine
cytidylyl-(3'-->5')-adenosine
DTXSID801310804
cytidine, adenylyl-(5'-->3')-
adenosine, cytidylyl-(3'-->5')-
Z59MA6MM9W

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" Dose-response curves for NECA were shifted to the right by the nonselective adenosine receptor antagonist 8(p-sulphophenyl)theophylline (8-SPT; 100 microM) and by the selective A1-receptor antagonist 1,3-dipropyl-8-cyclopentylxanthine (DPCPX; 1 mM)."( Species-dependent effects of adenosine receptor agonists on contractile responses of vas deferens to ATP.
Khoyi, MA; Moloney, S; Smith, AD; Westfall, DP, 1999
)
0.3
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (2)

ClassDescription
purinesA class of imidazopyrimidines that consists of purine and its substituted derivatives.
nucleoside analogueAn analogue of a nucleoside, being an N-glycosyl compound in which the nitrogen-containing moiety is a modified nucleotide base. They are commonly used as antiviral products to prevent viral replication in infected cells.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (34)

TimeframeStudies, This Drug (%)All Drugs %
pre-19906 (17.65)18.7374
1990's19 (55.88)18.2507
2000's8 (23.53)29.6817
2010's1 (2.94)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.11

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.11 (24.57)
Research Supply Index3.64 (2.92)
Research Growth Index4.74 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.11)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other37 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]